New combo aims to keep leukemia at bay after remission
NCT ID NCT07244367
First seen Nov 24, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether a combination of two drugs (cytarabine and venetoclax) can help adults with acute myeloid leukemia (AML) stay in remission longer. Participants are 18 to 60 years old who achieved complete remission after chemotherapy but cannot get a bone marrow transplant right away. The goal is to see if this maintenance therapy delays relapse and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Sohag university
RECRUITINGSohag, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sohag university hospital
RECRUITINGSohag, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.